BACKGROUND: Subclinical rejection, defined as histologic acute rejection in the absence of graft dysfunction, has been suggested as a cause of chronic allograft rejection. In cyclosporine-treated patients, the incidence of subclinical rejection 3 months after transplant is reported to be approximately 30%. The intent of our study was to determine the incidence of subclinical rejection in tacrolimus-treated renal allograft recipients. METHODS: We prospectively studied the incidence of subclinical rejection on surveillance biopsies performed 3 months after transplantation in 114 patients transplanted between September 1, 1998 and November 30, 2000. All patients received tacrolimus, mycophenolate mofetil, and prednisone, and 56% received antibody induction. RESULTS: Subclinical rejection was detected in 2.6% of patients (3/114, 95% confidence interval 0.5-7.5%). Borderline changes were detected in 11% (12/114). Subclinical rejections were treated with bolus methylprednisolone. CONCLUSIONS: The incidence of subclinical rejection early after kidney transplantation is extremely low in tacrolimus-treated patients in whom early rejections are aggressively treated, suggesting that surveillance biopsies may not be necessary with this regimen.
BACKGROUND: Subclinical rejection, defined as histologic acute rejection in the absence of graft dysfunction, has been suggested as a cause of chronic allograft rejection. In cyclosporine-treated patients, the incidence of subclinical rejection 3 months after transplant is reported to be approximately 30%. The intent of our study was to determine the incidence of subclinical rejection in tacrolimus-treated renal allograft recipients. METHODS: We prospectively studied the incidence of subclinical rejection on surveillance biopsies performed 3 months after transplantation in 114 patients transplanted between September 1, 1998 and November 30, 2000. All patients received tacrolimus, mycophenolate mofetil, and prednisone, and 56% received antibody induction. RESULTS: Subclinical rejection was detected in 2.6% of patients (3/114, 95% confidence interval 0.5-7.5%). Borderline changes were detected in 11% (12/114). Subclinical rejections were treated with bolus methylprednisolone. CONCLUSIONS: The incidence of subclinical rejection early after kidney transplantation is extremely low in tacrolimus-treated patients in whom early rejections are aggressively treated, suggesting that surveillance biopsies may not be necessary with this regimen.
Authors: Matthew P Welberry Smith; Rosamonde E Banks; Steven L Wood; Andrew J P Lewington; Peter J Selby Journal: Nat Rev Nephrol Date: 2009-10-27 Impact factor: 28.314
Authors: Petra Hrubá; Irena Brabcová; Faikah Gueler; Zdeněk Krejčík; Viktor Stránecký; Eva Svobodová; Jana Malušková; Wilfried Gwinner; Eva Honsová; Alena Lodererová; Rainer Oberbauer; Roman Zachoval; Ondřej Viklický Journal: Kidney Int Date: 2015-07-15 Impact factor: 10.612
Authors: Thangamani Muthukumar; John R Lee; Darshana M Dadhania; Ruchuang Ding; Vijay K Sharma; Joseph E Schwartz; Manikkam Suthanthiran Journal: Transplant Rev (Orlando) Date: 2014-05-27 Impact factor: 3.943
Authors: Michael E Seifert; Megan V Yanik; Daniel I Feig; Vera Hauptfeld-Dolejsek; Elizabeth C Mroczek-Musulman; David R Kelly; Frida Rosenblum; Roslyn B Mannon Journal: Am J Transplant Date: 2018-06-27 Impact factor: 8.086
Authors: Dirk Jan A R Moes; Rogier R Press; Oliver Ackaert; Bart A Ploeger; Frederike J Bemelman; Cheikh Diack; Judith A M Wessels; Tahar van der Straaten; Meindert Danhof; Jan-Stephan F Sanders; Jaap J Homan van der Heide; Henk Jan Guchelaar; Johan W de Fijter Journal: Br J Clin Pharmacol Date: 2016-05-10 Impact factor: 4.335